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severe infections, inflammation, and
allergy caused by ARPC1B deficiencyTo the Editor:
Recently, a novel syndrome of combined immunodeficiency,
allergy, and ‘‘auto’’inflammation caused by mutations in the
ARPC1B gene has been reported.1-4 Analysis of patient-derivedFIG 1. Clinical features, imaging, and histology of rele
clinical manifestations in ARPC1B-deficient patients (
and skin vasculitis in P7. E, Sialadenitis and lymph
GH, growth hormone.hematopoietic cells has shown a defect in actin polymerization,
which resulted in a wide range of clinical manifestations and
immunologic-hematologic features. We report on the immuno-
logic, cellular, and molecular phenotypes in 14 patients with
biallelic ARPC1B mutations and variable clinical presentations
(Fig 1, A andB; see Fig E1, A, and Table E1 in this article’s Online
Repository at www.jacionline.org; for case descriptions, see this
article’s Online Repository at www.jacionline.org), helping to
delineate the broad spectrum of this novel disease and presenting
unreported insights into cell-intrinsic defects involving regulatory
T (Treg) cells and natural killer (NK) cells, potential players in the
immune dysregulation and susceptibility to viral infections
observed in these patients. The disease-causing variants
are diverse and scattered throughout the gene (Fig E1, B;
Table E1). Patient (P) 4, P12, and P14 have Nepalese ancestry
and share the same variant, suggesting a founder mutation. In
all patient samples tested, ARPC1B protein was undetectable
by Western blotting and we identified an increased—although
variable—expression of the ARPC1A isoform (see Fig E2 in
this article’s Online Repository at www.jacionline.org).
The disease is characterized by a very early clinical onset
(mean, 2months; range, 1-6months) (see Table E2 in this article’s
Online Repository at www.jacionline.org). Presenting symptoms
included skin rash, infections, and gastrointestinal bleeding. Most
patients (79%) (Fig 1, A) suffered from recurrent or severe
bleeding episodes, most frequently represented by enterorrhagia.
Platelet counts were reduced (see Table E3 in this article’s Online
Repository at www.jacionline.org), with normal volume in most
cases. An increased rate and/or abnormal severity of respiratoryvant tissues in affected patients. A, Frequencies of
detailed in Table E8). B-D, Diffuse warts, eczema,
node enlargement in P3. CMV, cytomegalovirus;
FIG 2. Immune cell abnormalities. A, Representative plots of the altered B-lymphocyte staining (left panel),
B-lymphocyte percentage (middle panel), and CD19 expression (geometric mean fluorescence intensity,
right panel) in ARPC1B-deficient patients. For CD41 and CD81 T-cell subsets (naive, memory, and
effector-memory populations), see Fig E1. B, Treg-cell subset analysis with a representative dot plot showing
percentage of Treg cells (CD41CD25RAposCD127neg), and Treg FOXP3 and Helios expression. C, FOXP3 and
Helios expression of in vitro expanded Treg cells from patient and control (lines connect each patient with their
own healthy relative used as control). D, FACS plots showing the proliferation of allogeneic T-responder cells
(Tresp) measured by cell-trace violet (CTV) dilution. The stimulated and unstimulated Tresp without Treg cells
are shown in blue. Treg cells from controls (in gray) and patients (in red) were cultured at different ratios
with Tresp cells while stimulated with anti-CD3/CD28. E, Quantification of CD4 and CD8 Tresp-cell suppression
by Treg cells. F, NK cells of patients were functionally evaluated against the K562 cell line by CD107A
expression experiments. Resting NK cells (left panel) and IL-2–stimulated cells (right panel) were evaluated
and compared with 10 healthy controls. All controls are represented by healthy adults. Bars indicate
means 6 SD, and a star indicates statistical significance as assessed by Mann-Whitney test (P < .05).
Stim, Stimulated; unstim, unstimulated.
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LETTERS TO THE EDITOR 2297tract infections (including pneumonia, bronchopneumonia, and
bronchiolitis), and skin infections (including abscesses,
erysipelas, extensive warts [Fig 1, B], and molluscum
contagiosum), were observed in 71% and 50% of the patients,
respectively, whereas severe, protracted bacterial gastrointestinal
infections have been diagnosed in a minority of individuals
(see Tables E2 and E4 in this article’s Online Repository at
www.jacionline.org).
As summarized in Fig 1, A, and Table E5 (in this article’s
Online Repository at www.jacionline.org), common manifesta-
tions of immune dysregulation included moderate-to-severe
eczema, which was observed in 57% of cases (Fig 1, C),
associated with food allergy (anaphylactic reactions) and asthma.
Cutaneous vasculitis was noted in 69% of patients, presenting as a
maculopapular rash, erythema nodosum, or vasculitic purpura
(Fig 1, D). In all cases investigated with a skin biopsy,leukocytoclastic vasculitis was diagnosed. Arthritis was present
in 23% of patients. One child presented with 23 episodes of
macrophage activation syndrome, followed by the appearance
of enlarged lymph nodes, splenomegaly, and episodes of
sialadenitis (Fig 1, E). Autoantibodies were absent in most
patients. Growth failure was noted in all patients (Table E2),
with growth hormone tests found to be impaired when performed
(P2 and P3), compatible with a partial growth hormone
deficiency, and no catch-up growth after hematopoietic stem
cell transplantation (HSCT) (P2, P3, and P6).
Immunophenotyping showed an increased number of
circulating CD191 B cells, a reduced absolute count of
CD31CD41 and CD31CD81 T cells, and in 1 patient an
expansion of gd T cells, possibly driven by cytomegalovirus
infection (Fig 2, A; see Table E6 in this article’s Online
Repository at www.jacionline.org). In vivo immunoglobulin
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almost all cases (Table E6). In contrast to Wiskott-Aldrich
Syndrome or DOCK8 deficiency,5 the humoral response to
polysaccharide vaccine was normal in most cases (see Table E7
in this article’s Online Repository at www.jacionline.org). The
T-cell subset distribution was abnormal, with low percentages
of naive CD41 and CD81 T cells (see Fig E3, A and B, in this
article’s Online Repository at www.jacionline.org). In vitro
T-cell proliferation in response to combination of anti-
CD31 1 anti-CD281, cytokines (IL-15, IL-2), and mitogens
was largely normal, whereas response to low-dose CD3 and
antigens was defective in some cases (Table E7). The TCR
repertoire was persistently oligoclonal in 2 of 7 tested patients
and transiently oligoclonal in 1 patient (Fig E3, C; Table E6).
The proportion and phenotype of Treg cells was variable (Fig 2,
B; see Fig E4, A, in this article’s Online Repository at
www.jacionline.org); however, in vitro expanded Treg cells
showed decreased expression of all Treg-cell markers including
FOXP3, Helios, CD25, and CTLA-4 (Fig 2, C; Fig E4, B).
Treg-cell suppressor activity against CD41 (Fig 2, D and E)
and CD81 T allogeneic responder cells was defective (Fig E4,
C). An increase in the CD3-CD56brightCD16neg NK-cell
subpopulation (27% in P2, 24% in P3, and 21% in P4) was noted
when tested (P2, P3, and P4) (see Fig E5 in this article’s Online
Repository at www.jacionline.org; data not shown). Impaired
NK-cell degranulation in the presence of K562 cells was observed
and similarly to patients6 with Wiskott-Aldrich Syndrome IL-2
restored degranulation and killing to normal levels (Fig 2, F;
data not shown).
Most patients received antibiotic prophylaxis (71%). One
patient with recurrent oral candidiasis remained on antifungal
prophylaxis. ‘‘Auto’’inflammatory manifestations appear to
respond to steroids, mofetil mycophenolate, and sirolimus. The
response to TNF-blocking agents was unsatisfactory. To date, 5
patients have been treated with HSCT. Two patients have a
medium/long-term follow-up of 1 and 6 years, respectively, and
are in good health and off all medication (P2 and P6). The other 3
patients (P3, P9, and P12) have only recently been
transplanted, and they are alive and well, with resolution of all
‘‘auto’’inflammatory features.
In conclusion, our cohort delineates a more detailed and larger
spectrum of ARPC1B deficiency phenotypes compared with
previous reports. The clinical defect appears to be characterized
by recurrent bacterial and viral infections, extensive eczema,
allergies, thrombocytopenia, and skin vasculitis, together with
bleeding often manifested as early onset gastric hemorrhage and
hemorrhagic colitis. The eczematous skin phenotype can be
explained by immune-mediated allergic responses and the
anaphylactic reactions can be avoided by elimination of food
allergens from the diet. The defective Treg-cell function is
suggested to be involved in both the exaggerated TH2 responses
and IgE reactivity against allergens.7 Defects in cytoskeleton
rearrangement, altered immunologic synapses formation, and
reduced chemotaxis have been recently identified in
ARPC1B-deficient patients’ T cells,4 suggesting that they may
play a role in the susceptibility to infections. In addition, patients’
NK cells show a peculiar phenotypic profile and an impaired
functionality including both migration defects and NK-cell
dysfunction, which may well contribute to the predisposition to
viral infections seen in ARPC1B-deficient patients. Theneutrophil and macrophage abnormalities may explain the
susceptibility of the patients to bacterial infections1 in the
presence of normal antibody levels. Although careful monitoring,
antimicrobial prophylaxis, and adequate treatment are mandatory
to prevent and counter infections, the immunodysregulation
contributing to vasculitis and arthritis requires immunosuppres-
sion. The unique and variable combination of clinical features
makes ARPC1B deficiency a complex disease entity for which
HSCT is considered a curative treatment option.
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mu-1 null genotype increases wood
smoke-induced airway inflammationTo the Editor:
Particulate matter (PM) emissions from burning biomass are a
major source of indoor and outdoor air pollution. Wildland fires
also accounted for 20% of fine PM emissions in the United States
in 2012.1 Because climate change is associated with increased
severity and frequency of wildland fires throughout the world,
this problem is only expected to worsen with time.2
The often abrupt and significantly increased PM generated by
biomass combustion is associated with increased risk for
asthma, chronic obstructive pulmonary disease, pneumonia, and
cardiovascular disease. Wildfire smoke exposure causes
increased emergency department visits, hospitalizations, and
premature deaths.3 Firefighters deployed to wildland fires are
frequently exposed to PM levels well in excess of the
National Ambient Air Quality Standards for PM with a diameter
of 2.5 mm or less (PM2.5) or PM with a diameter of 10 mm or less
(PM10). Field studies of wildland firefighters reported
worsened lung function and increased nonspecific bronchial
reactivity during a fire season compared with preseason values.4
Neutrophil counts and inflammatory cytokine levels were
increased in the airways and peripheral blood of firefighters after
work shifts.5
Intracellular antioxidant enzymes, such as glutathione-S-
transferase mu-1 (GSTM1), regulate cellular and mucosal
oxidative stress. We have previously shown that patients with
the GSTM1-null genotype (resulting in absence of GSTM1
protein) have increased susceptibility for development of
neutrophilic bronchitis after exposure to diverse air pollutants,
